AngioDynamics (ANGO) Securities Lawsuit Investigation
Our attorneys are investigating potential claims on behalf of investors of AngioDynamics, Inc. (NASDAQ: ANGO) regarding possible securities law violations.
AngioDynamics Losses?
If you purchased or otherwise acquired shares in AngioDynamics and would like to learn more about the investigation, contact us to speak privately with a securities attorney.
News of 'Material Weakness' Causes Share Price to Fall 7.5%
After the close of trading on July 17, 2017, AngioDynamics, Inc. announced that its auditor found a material weakness in its internal control over financial reporting as of May 31, 2016 because it did not design and maintain effective internal controls over the accounting for the annual goodwill impairment test. Specifically, it did not have effective controls to review in sufficient detail the cash flow projections and valuation model assumptions used in the goodwill impairment test as of December 31, 2015.
Following this news, on July 18, 2017 the company’s share price fell by 7.5% in intraday trading, causing significant harm to investors.
Our Reputation for Excellence
Girard Gibbs LLP is one of the nation’s leading firms representing individual and institutional investors in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and has earned Tier-1 rankings and been named in the U.S. Lawyers – Best Law Firms list for four consecutive years.
